Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Deuruxolitinib · 1 trial · 1 indication
SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).
| Arm | Type | Description |
|---|---|---|
| Deuruxolitinib 8 mg | EXPERIMENTAL | Participants in this arm will receive deuruxolitinib 8 mg administered orally twice daily (BID) during the 24-week double-blind treatment period and continue to receive deuruxolitinib 8 mg administered orally BID up to 52 weeks |
| Placebo | PLACEBO_COMPARATOR | Participants in this arm will receive matching placebo administered orally BID during the 24-week double-blind treatment period and then receive deuruxolitinib 8 mg administered orally BID up to 52 weeks. |
| Name | Type | Description |
|---|---|---|
| Deuruxolitinib | DRUG | Deuruxolitinib will be dosed orally as tablets at a dose of 8 mg |
| Placebo | DRUG | Deuruxolitinib matching placebo will be dosed orally as tablets for up to 24 weeks and then deuruxolitinib will be dosed for up to 52 weeks |
Inclusion Criteria: * Written informed consent has been obtained. * Japanese subjects with severe alopecia areata who are between 18 and 65 years of age, inclusive, at the time of informed consent. * Definitive diagnosis of alopecia areata with a current episode of scalp hair loss lasting at least ...